Cryoport, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. on April 6, 2012, reporting events occurring on April 2, 2012. The filing addresses the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes.
Material Changes
The primary material change is the appointment of Steven Leatherman as Chief Commercial Officer. Mr. Leatherman brings over 30 years of experience in healthcare sales, marketing, and operations, with previous leadership roles at Ansell Sandel Medical Solutions, Sandel Medical Industries, Microflex, Bausch & Lomb, Carl Zeiss Surgical, Terumo Heart, and Biotronik.
Compensation and Equity Grant Details
- Base Salary: $235,000 annually.
- Incentive Bonus: Targeted at 30% of the annual base salary.
- Stock Option Grant 1: 150,000 shares at an exercise price of $0.62 per share. Vesting occurs over four years, with 18,750 shares vesting every six months.
- Stock Option Grant 2: 100,000 shares at an exercise price of $0.62 per share. Vesting is performance-based:
- 50,000 shares vest upon achieving 5,000 shipments per month.
- 50,000 shares vest upon achieving six months of sustainable positive cash flow as determined by the Board of Directors.
Outlook and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the standard requirements of the form. The performance-based vesting conditions imply a strategic focus on increasing shipment volume and achieving positive cash flow.
Key Facts for Investor Verification
- Verify the Company's current monthly shipment volume against the 5,000 unit threshold for the performance-based stock options.
- Review recent financial statements to assess the Company's proximity to the "sustainable positive cash flow" milestone required for the second tranche of stock options.
- Confirm the total dilution impact of the 250,000 new stock options granted to the new Chief Commercial Officer.
- Monitor the Company's cash burn rate given the new executive compensation structure and the cash flow vesting condition.